204 related articles for article (PubMed ID: 29846248)
1. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
[TBL] [Abstract][Full Text] [Related]
2. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
[No Abstract] [Full Text] [Related]
3. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.
Franken M; Kanters T; Coenen J; de Jong P; Jager A; Groot CU
Breast; 2020 Aug; 52():71-77. PubMed ID: 32447129
[TBL] [Abstract][Full Text] [Related]
4. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
[TBL] [Abstract][Full Text] [Related]
5. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
[TBL] [Abstract][Full Text] [Related]
7. [Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)].
Favier M; Le Goc-Sager F; Vincent-Cantini I; Launay V; Giroux EA; Lièvremont K; Bonnet I; Barbe C; Duval E; Loric N; Delbaldo C
Bull Cancer; 2018 Oct; 105(10):862-872. PubMed ID: 30244982
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites.
Stewart DA; Boudreault JS; Maturi B; Boras D; Foley R
Curr Oncol; 2018 Oct; 25(5):300-306. PubMed ID: 30464679
[TBL] [Abstract][Full Text] [Related]
9. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
Olsen J; Jensen KF; Olesen DS; Knoop A
J Comp Eff Res; 2018 May; 7(5):411-419. PubMed ID: 29199854
[TBL] [Abstract][Full Text] [Related]
10. Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion.
Mihajlović J; Bax P; van Breugel E; Blommestein HM; Hoogendoorn M; Hospes W; Postma MJ
Clin Ther; 2017 Jun; 39(6):1221-1232.e4. PubMed ID: 28579210
[TBL] [Abstract][Full Text] [Related]
11. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
[TBL] [Abstract][Full Text] [Related]
12. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
13. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
16. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
Harvey MJ; Zhong Y; Morris E; Beverage JN; Epstein RS; Chawla AJ
PLoS One; 2022; 17(1):e0261336. PubMed ID: 35073335
[TBL] [Abstract][Full Text] [Related]
17. Intravenous versus subcutaneous trastuzumab: an economic and patient perspective.
Mitchell H; Morrissey D
Br J Nurs; 2019 May; 28(10):S15-S20. PubMed ID: 31116603
[TBL] [Abstract][Full Text] [Related]
18. Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study.
Abad-Sazatornil MR; Arenaza A; Bayo J; García Mata J; Guinea De Castro JM; León J; Letellez J; Reguero V; Martínez Chamorro C; Salar A
BMC Health Serv Res; 2021 Apr; 21(1):320. PubMed ID: 33832464
[TBL] [Abstract][Full Text] [Related]
19. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
[TBL] [Abstract][Full Text] [Related]
20. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]